Edgewise Therapeutics (EWTX) EBITDA (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of EBITDA data on file, last reported at -$54.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 17.75% year-over-year to -$54.1 million; the trailing twelve-month figure through Mar 2026 stood at -$199.6 million (down 17.36% YoY), and the FY2025 full-year result was -$191.4 million, down 20.51% from the prior year.
• EBITDA rose to -$54.1 million in Q1 2026, from -$56.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$14.8 million in Q1 2022 to a low of -$56.0 million in Q4 2025.
• A 5-year average of -$34.7 million and a median of -$34.8 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 116.22% in 2022 and fell 11.82% in 2025, its largest moves.
• Tracing EWTX's EBITDA over 5 years: stood at -$22.1 million in 2022, then plunged by 53.37% to -$33.9 million in 2023, then sank by 34.49% to -$45.5 million in 2024, then fell by 22.92% to -$56.0 million in 2025, then increased by 3.33% to -$54.1 million in 2026.
• Business Quant data shows EWTX's EBITDA at -$54.1 million in Q1 2026, -$56.0 million in Q4 2025, and -$46.9 million in Q3 2025.